Physician-Led Switching From Reference Biologics to Biosimilars: What Is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany?

Value in Health · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles